Agilux Laboratories Announces Space Expansion to Support Increasing Demand for Its In Vivo Pharmacokinetics Services

WORCESTER, Mass.--Agilux Laboratories, a leading provider of Drug Metabolism and Pharmacokinetics (DMPK) services to pharmaceutical and biotechnology firms, announced today that it has undergone a significant space expansion of its in vivo pharmacokinetics services to support clients' demands and increased service requirements. This space expansion will allow Agilux to significantly increase its capacity and volume while maintaining its historically fast study starts.

As a result of this space expansion, Agilux has more than doubled its dedicated vivarium space which enables an increase in all in vivo services with potential for additional species and genders. By doubling its commitment to additional in vivo space, Agilux is immediately able to ramp up to utilize 50% of the new space with additional capacity available to its steadily growing client base.

"Investing in the current and future growth of this facility and our in vivo capabilities ensures that we can continue to service existing and prospective clients in the fastest, most flexible and efficient manner possible." said Jim Jersey, President and CEO. "The iterative nature of in vivo pharmacokinetic screening requires rapid cycle times with turn-on-a-dime changes in priorities. This important expansion will help us support our clients' demands, while allowing for the continuance of rapid study initiations that are a hallmark of Agilux's in vivo capabilities."

About Agilux Laboratories Inc.

Agilux Laboratories Inc., with over 90 employees and greater than 50,000 square feet of facility space, is a leading New England-based contract research organization (CRO) that has developed into one of the fastest growing CRO's in the Boston/Cambridge biotech arena. Agilux Labs is driven by its ability to offer "Better Data Faster" across a broad range of services supporting drug discovery, pre-clinical and clinical services. Our full range of Drug Metabolism and Pharmacokinetic services, include fit-for-purpose rapid turnaround LC-MS/MS Bioanalysis, In-Vivo PK, and In-Vitro Assay services. With corresponding clinical site support, GLP LC-MS/MS Bioanalytical services are also provided to support regulated pre-clinical and clinical studies. To learn more, please visit us at

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.